Moderna (NASDAQ: MRNA) made headlines on Wednesday when its personalized mRNA cancer vaccine, developed in collaboration with Merck (NYSE: MRK), became the first such therapy to succeed in a late-stage trial. This breakthrough reduced the risk of melanoma recurrence and resulted in a staggering 177% surge in Moderna’s stock price, marking a significant advancement for the mRNA platform and potential future cancer treatments.
The iShares Biotechnology ETF (NASDAQ: IBB) is also experiencing growth, up about 25% year-to-date, particularly gaining momentum over the last month. Two companies within this sector, Eli Lilly (NYSE: LLY) and Natera (NASDAQ: NTRA), are positioned to capitalize on this trend. Eli Lilly, the largest pharmaceutical firm by market cap at $1.2 trillion, is up over 15% in 2023 and is venturing into oral GLP-1 medications. Meanwhile, Natera, specializing in cell-free DNA testing, has seen its stock rise over 40% year-to-date and recorded annual sales exceeding $2.3 billion.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
